Aripiprazole Autism Treatment Research List
2012 Research
→A Retrospective Review of the Effectiveness of Aripiprazole in the Treatment of Sensory Abnormalities in Autism
- Summary coming soon!
→Aripiprazole in the Treatment of Challenging Behaviour in Adults with Autism Spectrum Disorder
- Summary coming soon!
→Effect of Aripiprazole 2 to 15 mg/d on Health-Related Quality of Life in the Treatment of Irritability Associated with Autistic Disorder in Children: A Post Hoc Analysis of Two Controlled Trials
- A post-hoc analysis design
- Analyzed data from two 8-week placebo-controlled, randomized, double-blinded studies utilizing aripiprazole in children with autism
- Focused on the effect of aripiprazole on health-related quality of life in children with autism spectrum disorders
2011 Research
→Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients: Patient Profile
- Research summary not available
→Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients with Autistic Disorder: A 52-Week, Open-Label, Multicenter Study
- An open-label, flexibly-dosed study
- Included 330 children with autism, 199 of which completed the 52-week study
- Focused on the long-term safety and tolerability of Abilify (aripiprazole) including extrapyramidal symptoms, weight gain, metabolic measures, vital signs, and other adverse events
→Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Pediatric Subjects (6-17 Years Old): Results from a Pooled Analysis of 2 Studies
- Data obtained from 2 different 8-week, randomized, double-blind, multicenter, placebo-controlled studies
- Included 313 children with autism spectrum disorders
- Focused on safety and tolerability of Abilify (aripiprazole) including sedation, fatigue, vomiting, increased appetite, body weight changes
→Aripiprazole in the Treatment of Irritability in Pediatric Patients (6-17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study
- A 52-week, open-label, flexible-dose study
- Included 313 children with autism
- Focused on efficacy of Abilify in treating irritability and also focused on Clinical Global Impressions-Improvement score
→Aripiprazole: In the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients
- Data obtained from 2 different 8-week, randomized, double-blind, placebo-controlled studies and a 52-week study
- Focused on tolerability of Abilify (aripiprazole) and efficacy in treating irritability
→A Prospective Open-Label Study of Aripiprazole in Fragile X Syndrome
- Fragile X syndrome is the most common single gene source of autism
- A prospective, 12-week, open-label study
- Included 12 individuals with fragile X syndrome
- Focused on impact of Abilify on irritability and Clinical Global Impressions-Improvement score
→Aripiprazole for the Treatment of Irritability Associated with Autism
- An opinion paper
- Discusses pharmacokinetics, pharmacodynamics, safety and efficacy of Abilify (aripiprazole)
- Also discusses mechanism of action of Abilify and why it may have a better side effect profile than other drugs used to treat irritability in autism
→Aripiprazole to Treat Irritability Associated with Autism: A Placebo-Controlled, Fixed-Dose Trial
- A placebo-controlled, fixed-dose, parallel group study
- Included 218 children with autism
- Focused on safety of aripiprazole and efficacy in treating irritability associated with autism
2010 Research
→Aripiprazole for Irritability Associated with Autistic Disorder in Children and Adolescents Aged 6-17 Years
- A review article
- Cites 2 different 8-week trials looking at safety and tolerability of Abilify (aripiprazole) and previous research conducted utilizing aripiprazole
- Also discusses the chemistry, pharmacokinetics, metabolism, and mechanism of action of Abilify
→Aripiprazole Treatment for Coprophagia in Autistic Disorder
- Research summary not available
- Coprophagia is the consumption of feces
→Line-Item Analysis of the Aberrant Behavior Checklist: Results from Two Studies of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder
- Analyzed data from two different 8-week, randomized, double-blind, multicenter studies
- Focused on the effect of Abilify (aripiprazole) on the Aberrant Behavior Checklist including mood changing quickly, cries/screams inappropriately, stamps feet/bangs objects, tantrum-like behaviors, self-injurious behaviors, and hyperkinesis
→Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
- A review article
- Discusses background of autism and fragile X syndrome
- Overview of research for the use of Abilify (aripiprazole) for autism and fragile X syndrome
→Aripiprazole Improves Social Interaction in Taiwanese Children with Pervasive Developmental Disorder
- A case report
- Included 3 children with pervasive development disorder
- Focused on impact of Abilify on social interaction and on depression/anxiety
2009 Research
→Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autistic Disorder
- A double-blind, randomized, placebo-controlled, parallel group study
- Included 98 children with autism
- Focused on efficacy of Abilify (aripiprazole) in treating tantrums, aggression, and/or self-injurious behavior
→A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder
- A randomized, placebo-controlled, parallel group, fixed-dose study
- Included 218 children with autism spectrum disorders
- Focused on short-term safety and efficacy of Abilify in treating irritability (tantrums, aggression, and/or self-injurious behavior)
→Waxing-and-Waning Catatonia After Intermittent Exposure to Aripiprazole in a Case of Autism and Bipolar Disorder
- Research summary not available
→Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger’s Disorder: a 14-week, Prospective, Open-Label Study
- A prospective, open-label study
- Included 25 children with Asperger’s or PDD-NOS
- Focused on the safety and efficacy of Abilify (aripiprazole) in treating irritability (aggression, self-injurious behavior, and tantrums)
→Aripiprazole Monotherapy in Children and Young Adolescents with Pervasive Developmental Disorders: a Retrospective Study
- A retrospective study
- Included 35 children with pervasive developmental disorder
- Focused on safety and efficacy of aripiprazole in treating aggression against self and/or others, hostility, hyperactivity, and severe impulsiveness
2006 Research
→Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents with Developmental Disabilities
- A retrospective chart review study
- Included 32 children, 18 of which had autism
- Focused on safety and efficacy of Abilify (aripiprazole) in treating aggression, hyperactivity, impulsivity, and self-injurious behaviors
→Aripiprazole Use in Individuals with Intellectual Disability and Psychotic or Behavioural Disorders: a Case Series
- A case series study
- Included 5 individuals, 1 of which had autism
- Focused on the safety and efficacy of Abilify
2005 Research
→Aripiprazole in Children and Adolescents: Clinical Experience
- A retrospective and prospective study
- Included 17 children with autism, 16 of which had autism
- Focused on adverse events and efficacy of Abilify (aripiprazole) in treating mood instability, aggression, and psychosis
Additional Resources:
- More Information on Autism Treatments
- More Information About Autism
Follow Ultimate Autism Guide!